netFormulary Harrogate & Rural District Formulary NHS
Harrogate & District NHS Foundation Trust
Harrogate & Rural District Clinical Commissioning Group
 
 
 Search
 Formulary Chapter 10: Musculoskeletal and joint diseases - Full Chapter
10.01.03  Expand sub section  Drugs which suppress the rheumatic disease process
10.01.03  Expand sub section  Gold
10.01.03  Expand sub section  Penicillamine
10.01.03  Expand sub section  Antimalarials
10.01.03  Expand sub section  Drugs affecting the immune response to top
Azathioprine
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber Shared Care

Tablets 25mg, 50mg

 
Link  Azathioprine Shared Care Guidelines
   
Cytotoxic Drug Methotrexate (Rheumatology)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Tablets 2.5mg

Injection (various strengths available in pre-filled syringes)

 
Link  Methotrexate Shared Care Guidelines
   
Baricitinib (Olumiant)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Grey
High Cost Medicine
 
Link  NICE TA466 Baricitinib for moderate to severe rheumatoid arthritis
   
Ciclosporin
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber Shared Care
Capsules 25mg, 50mg, 100mg

Due to differences in bioavailability, patients must remain on the same brand of immunosuppressant except on the advice of specialist clinician. MUST be prescribed by brand. 
Link  Ciclosporin Shared Care Guidelines
   
Leflunomide (Arava)
View adult BNF View SPC online View childrens BNF
Formulary Tablets 10mg 
Link  Leflunomide Shared Care Guidelines
   
Cytotoxic Drug Rituximab (Truxima)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
Initiation on the advice of a specialist 
Link  Rituximab (Rapid) Chart
Link  Rituximab Chart
   
Sarilumab
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
 
Link  NICE TA485 Sarilumab for moderate to severe rheumatoid arthritis
   
Tocilizumab (RoActemra)
(20mg/ml Concentrate for Solution for Infusion)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
Homecare
 
Link  NICE TA518 - Tocilizumab for treating giant cell arteritis
   
Tocilizumab (RoActemra)
(162mg Pre-filled Syringe for Subcutaneous Administration)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
Homecare

Approved by the HaRD Area Prescribing Committee, January 2015

 
Link  NICE TA518 - Tocilizumab for treating giant cell arteritis
   
Tofacitinib (Xeljanz )
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Grey
High Cost Medicine
For initiation by Consultant Rheumatologists  
Link  NICE TA480 Tofacitinib for moderate to severe rheumatoid arthritis
   
Adalimumab (Humira)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Amber
Homecare

Initiation by Consultant Rheumatologists only

 
Link  NICE TA455 - Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
   
Certolizumab Pegol (Cimzia)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Amber
Homecare

Initiation by a Consultant Rheumatologist

 
Link  NICE TA445 - Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
   
Etanercept (Benepali)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
Homecare

Initiated by consultant rheumatologist or dermatologist only.

 
Link  TA455 - Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
   
Infliximab (Remicade)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted Initiation on the advice of a specialist 
   
Etanercept (Enbrel)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Amber
Homecare

Initiation by Consultant Rheumatologists only

 
Link  - TA455 - Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
   
Abatacept (Orencia)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
Homecare

Initiation by Consultant Rheumatologists only.

Commissioned by NHS England

 
   
10.01.03  Expand sub section  Cytokine modulators
10.01.03  Expand sub section  Sulfasalazine
 ....
 Non Formulary Items
Anakinra  (Kineret)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Amber

Medicines which are suitable to be prescribed in primary care only after specialist recommendation. Ongoing prescribing by primary care includes titration of dose and assessment of efficacy. There is no need for ongoing monitoring other than for general adverse effects as listed in the BNF & SPC.  

Amber Shared Care

Medicines which are suitable to be prescribed in primary care only after specialist recommendation only under a shared care protocol once the patient has been stabilised. Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must be approved by the Harrogate & Rurual District Area Prescribing Committee (HaRD APC).   

Black

Medicines which the Harrogate & Rural District Area Prescribing Committee (HaRD APC) has reviewed and does not recommend for use at present based on a review of clinical and/or cost effectiveness data.   

Green

Medicines suitable for routine use and can be prescribed within primary care within their licensed indication in accordance with nationally recognised formularies e.g. BNF, BNF for Children, Palliative Care Formulary. Primary care prescribers take full responsibility for prescribing.  

Grey

Medicines which the Harrogate & Rural District Area Prescribing Committee (HaRD APC) have not yet reviewed.   

Red

Medicines for hospital use only. The responsibility for initiation and monitoring treatment should rest with an appropriate hospital clinician. The drug should be supplied by the hospital for the duration of the treatment course. Primary care prescriber initiation or continuation of treatemnt is not recommended.  

netFormulary